Display options
Cite
Sayiner M, Stepanova M, Pham H, et al. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016;3(1):e000106doi: 10.1136/bmjgast-2016-000106.
Sayiner, M., Stepanova, M., Pham, H., Noor, B., Walters, M., & Younossi, Z. M. (2016). Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ open gastroenterology, 3(1), e000106. https://doi.org/10.1136/bmjgast-2016-000106
Sayiner, Mehmet, et al. "Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease." BMJ open gastroenterology vol. 3,1 (2016): e000106. doi: https://doi.org/10.1136/bmjgast-2016-000106
Sayiner M, Stepanova M, Pham H, Noor B, Walters M, Younossi ZM. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016 Aug 16;3(1):e000106. doi: 10.1136/bmjgast-2016-000106. eCollection 2016. PMID: 27648297; PMCID: PMC5013331.
Copy Download .nbib Format: NLM
Share it on

BMJ Open Gastroenterol. 2016 Aug 16;3(1):e000106. doi: 10.1136/bmjgast-2016-000106. eCollection 2016.

Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease.

BMJ open gastroenterology

Mehmet Sayiner, Maria Stepanova, Huong Pham, Bashir Noor, Mercedes Walters, Zobair M Younossi

Affiliations

  1. Betty and Guy Beatty Center for Integrated Research, Inova Health System , Falls Church, Virginia , USA.
  2. Department of Medicine , Center for Liver Diseases, Inova Fairfax Hospital , Falls Church, Virginia , USA.
  3. Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA; Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia, USA.

PMID: 27648297 PMCID: PMC5013331 DOI: 10.1136/bmjgast-2016-000106

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease associated with increased liver-related mortality. Additionally, NAFLD could potentially impair health-related quality of life. Although an approved treatment for NAFLD does not exist, a number of new drugs for treatment of NAFLD are being developed. As the efficacy and safety of these regimens are being established, their cost-effectiveness, which requires the use of quality of life metrics and health utility scores to quality-adjusted outcomes, must also be assessed. The aim of this study was to report quality of life and health utilities in patients with NAFLD with and without cirrhosis for future use.

METHODS: Patients with NAFLD were seen in an outpatient clinic setting. Each patient had extensive clinical data and completed the Short Form-36 (SF-36 V.1) questionnaire. The SF-6D health utility scores were calculated.

RESULTS: There were 89 patients with the spectrum of NAFLD completed the SF-36 questionnaire: 59 with non-cirrhotic NAFLD and 30 with cirrhosis. Patients with NAFLD had significantly lower quality of life and health utility scores than the general population (all p<0.0001). Furthermore, patients with cirrhosis had lower quality of life and utility scores than non-cirrhotic NAFLD patients: SF-6D 0.660±0.107 in non-cirrhotic NAFLD vs 0.551±0.138 in cirrhotic NAFLD (p=0.0003).

CONCLUSIONS: Health utilities and quality of life scores are impaired in patients with cirrhotic NAFLD. These values should be used in cost-effectiveness analysis of the upcoming treatment regimens for advanced NAFLD.

Keywords: CIRRHOSIS; FATTY LIVER; NONALCOHOLIC STEATOHEPATITIS; QUALITY OF LIFE

References

  1. Value Health. 2009 Mar-Apr;12(2):346-53 - PubMed
  2. Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S383-412 - PubMed
  3. Med Care. 2007 Dec;45(12):1162-70 - PubMed
  4. J Clin Epidemiol. 1998 Nov;51(11):903-12 - PubMed
  5. J Clin Exp Hepatol. 2012 Jun;2(2):135-44 - PubMed
  6. Aliment Pharmacol Ther. 2007 Sep 15;26(6):815-20 - PubMed
  7. Health Policy Plan. 2006 Sep;21(5):402-8 - PubMed
  8. J Clin Gastroenterol. 2015 Mar;49(3):222-7 - PubMed
  9. Gastroenterology. 2008 Jan;134(1):85-94 - PubMed
  10. Curr Gastroenterol Rep. 2013 Jan;15(1):301 - PubMed
  11. Annu Rev Public Health. 2000;21:587-611 - PubMed
  12. Expert Rev Gastroenterol Hepatol. 2016;10(1):63-71 - PubMed
  13. Health Qual Life Outcomes. 2016 Feb 09;14:18 - PubMed
  14. Med Decis Making. 2016 Feb;36(2):147-59 - PubMed
  15. BMJ Open. 2014 May 16;4(5):e004318 - PubMed
  16. J Health Econ. 2007 May 1;26(3):597-612 - PubMed
  17. Gastroenterology. 2009 Apr;136(4):1134-44 - PubMed
  18. Am J Gastroenterol. 2001 Jul;96(7):2199-205 - PubMed
  19. Metabolism. 2016 Aug;65(8):1017-25 - PubMed
  20. Aliment Pharmacol Ther. 2014 Sep;40(6):676-85 - PubMed
  21. Hepatology. 2009 Jun;49(6):1904-12 - PubMed
  22. Pharmacoeconomics. 2015 Dec;33(12 ):1245-53 - PubMed
  23. Hepat Mon. 2013 May 08;13(5):e7382 - PubMed
  24. JAMA. 1996 Oct 23-30;276(16):1339-41 - PubMed
  25. Gastroenterology. 2016 Jun;150(8):1778-85 - PubMed
  26. Hepatology. 2016 Jul;64(1):73-84 - PubMed
  27. Aliment Pharmacol Ther. 2009 Sep 1;30(5):469-76 - PubMed
  28. Hepatology. 2012 Jun;55(6):2005-23 - PubMed

Publication Types